Neoadjuvant proton beam irradiation vs. adjuvant ruthenium brachytherapy in transscleral resection of uveal melanoma

Abstract

Background

Uveal melanoma is the most common primary ocular malignancy in adults in the USA and Europe. The optimal treatment of large uveal melanoma is still under debate. Radiation therapy has its limitation due its eye-threatening secondary complications and is therefore often combined with surgical excision of the tumor.

Methods

In a retrospective interventional review, we evaluated in total 242 patients with uveal melanoma that underwent transscleral tumor resection with a predefined protocol, either with adjuvant ruthenium brachytherapy (Ru-106 group, n 136,), or with neoadjuvant proton beam therapy (PBT group, n 106). Kaplan-Meier estimates with log-rank test were used to show survival curves and a multivariable Cox regression model was used to calculate adjusted rate ratios.

Results

Local tumor recurrence rates after 3 and 5 years were 4% (95% CI 1.2–17.8%) and 9.1% (95% CI 2.9–27.3%), respectively, in the PBT group and 24.6% (95% CI 15.8–37.1%) and 27.5 (95% CI 17.8–41.1%), respectively, in the Ru-106 group. This leads to an overall recurrence rate almost 4 times higher in the Ru-106 group compared to the PBT group. After adjusting for the a priori confounders and the tumor distance to optic disc and ciliary body infiltration, the adjusted risk of tumor recurrence was 8 times (RR 7.69 (2.22–26.06), p < 0.001) higher in the Ru-106 group as compared to the PBT group. Three- and 5-year metastatic rates were 23.2% (95% CI 5.6–37.1%) and 31.8% (95% CI 20.7–46.8%), respectively, in the PBT group and 13.2% (95% CI 6.8–24.9%) and 30.3% (95% CI 18.3–47.5%), respectively, in the Ru-106 group. There was no statistically significant difference in the overall metastasis rate between the two groups even after adjusting for possible confounders.

Conclusion

Transscleral resection of large uveal melanomas combined with neoadjuvant proton beam therapy leads to a lower local tumor recurrence rate compared to transscleral tumor resection with adjuvant ruthenium brachytherapy. There was no statistically significant difference in the occurrence of rubeosis iridis, neovascular glaucoma, and in the need for enucleation later on.

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2
Fig. 3

References

  1. 1.

    Collaborative Ocular Melanoma Study G (2006) The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: V. Twelve-year mortality rates and prognostic factors: COMS report no. 28. Arch Ophthalmol 124:1684–1693. https://doi.org/10.1001/archopht.124.12.1684

    Article  Google Scholar 

  2. 2.

    Lommatzsch PK (1986) Results after beta-irradiation (106Ru/106Rh) of choroidal melanomas: 20 years experience. Br J Ophthalmol 70:844–851

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  3. 3.

    Puusaari I, Heikkonen J, Summanen P, Tarkkanen A, Kivelä T (2003) Iodine brachytherapy as an alternative to enucleation for large uveal melanomas. Ophthalmology 110:2223–2234. https://doi.org/10.1016/S0161-6420(03)00661-4

    Article  PubMed  Google Scholar 

  4. 4.

    Conway R, Poothullil AM, Daftari IK, Weinberg V, Chung JE, O’Brien JM (2006) EStimates of ocular and visual retention following treatment of extra-large uveal melanomas by proton beam radiotherapy. Arch Ophthalmol 124:838–843. https://doi.org/10.1001/archopht.124.6.838

    Article  PubMed  Google Scholar 

  5. 5.

    Lumbroso L, Desjardins L, Levy C, Plancher C, Frau E, D’Hermies F, Schlienger P, Mammar H, Delacroix S, Nauraye C, Ferrand R, Desblancs C, Mazal A, Asselain B (2001) Intraocular inflammation after proton beam irradiation for uveal melanoma. Br J Ophthalmol 85:1305–1308. https://doi.org/10.1136/bjo.85.11.1305

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  6. 6.

    Saornil MA, Egan KM, Gragoudas ES, Seddon JM, Walsh SM, Albert DM (1992) HIstopathology of proton beam-irradiated vs enucleated uveal melanomas. Arch Ophthalmol 110:1112–1118. https://doi.org/10.1001/archopht.1992.01080200092031

    Article  PubMed  CAS  Google Scholar 

  7. 7.

    Muller HK, Lund OE, Sollner F, Seidel G (1966) The operative treatment of tumors of the chamber angle and ciliary body. Doc Ophthalmol 20:500–518

    Article  PubMed  CAS  Google Scholar 

  8. 8.

    Stallard HB (1966) Partial choroidectomy. Br J Ophthalmol 50:660–662

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  9. 9.

    Bechrakis NE, Petousis V, Willerding G, Krause L, Wachtlin J, Stroux A, Foerster MH (2010) Ten-year results of transscleral resection of large uveal melanomas: local tumour control and metastatic rate. Br J Ophthalmol 94:460–466. https://doi.org/10.1136/bjo.2009.162487

    Article  PubMed  Google Scholar 

  10. 10.

    Damato BE, Paul J, Foulds WS (1996) Risk factors for metastatic uveal melanoma after trans-scleral local resection. Br J Ophthalmol 80:109–116

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  11. 11.

    Kivelä T, Puusaari I, Damato B (2003) Transscleral resection versus iodine brachytherapy for choroidal malignant melanomas 6 millimeters or more in thickness: a matched case–control study. Ophthalmology 110:2235–2244. https://doi.org/10.1016/j.ophtha.2003.02.001

    Article  PubMed  Google Scholar 

  12. 12.

    Willerding GD, Cordini D, Moser L, Krause L, Foerster MH, Bechrakis NE (2015) Neoadjuvant proton beam irradiation followed by transscleral resection of uveal melanoma in 106 cases. Br J Ophthalmol. https://doi.org/10.1136/bjophthalmol-2015-307095

  13. 13.

    Foulds WS (1973) The local excision of choroidal melanomata. Trans Ophthalmol Soc U K 93:343–346

    PubMed  CAS  Google Scholar 

  14. 14.

    Foulds WS (1995) Local resection and other conservative therapies for intraocular melanoma. Curr Opin Ophthalmol 6:62–69

    Article  PubMed  CAS  Google Scholar 

  15. 15.

    Damato B, Groenewald CP, McGalliard JN, Wong D (2002) Rhegmatogenous retinal detachment after transscleral local resection of choroidal melanoma. Ophthalmology 109:2137–2143

    Article  PubMed  Google Scholar 

  16. 16.

    Bechrakis NE, Bornfeld N, Zöller I, Foerster MH (2002) Iodine 125 plaque brachytherapy versus transscleral tumor resection in the treatment of large uveal melanomas. Ophthalmology 109:1855–1861. https://doi.org/10.1016/S0161-6420(02)01273-3

    Article  PubMed  Google Scholar 

  17. 17.

    Barbara D, Rolf B (2002) Precise modelling of the eye for proton therapy of intra-ocular tumours. Phys Med Biol 47:593

    Article  Google Scholar 

  18. 18.

    Marnitz S, Cordini D, Bendl R, Lemke A-J, Heufelder J, Simiantonakis I, Kluge H, Bechrakis NE, Foerster MH, Hinkelbein W (2006) Proton therapy of uveal melanomas. Strahlenther Onkol 182:395–399. https://doi.org/10.1007/s00066-006-1512-1

    Article  PubMed  Google Scholar 

  19. 19.

    Goitein M, Miller T (1983) Planning proton therapy of the eye. Med Phys 10:275–283. https://doi.org/10.1118/1.595258

    Article  PubMed  CAS  Google Scholar 

  20. 20.

    Heufelder J, Cordini D, Fuchs H, Heese J, Homeyer H, Kluge H, Morgenstern H, Hocht S, Nausner M, Bechrakis NE, Hinkelbein W, Foerster MH (2004) Five years of proton therapy of eye neoplasms at the Hahn-Meitner Institute, Berlin. Z Med Phys 14:64–71

    Article  PubMed  Google Scholar 

  21. 21.

    Damato BE (2012) Local resection of uveal melanoma. Dev Ophthalmol 49:66–80. https://doi.org/10.1159/000328261

    Article  PubMed  Google Scholar 

  22. 22.

    Gallie BL, Simpson ER, Saakyan S, Amiryan A, Valskiy V, Finger PT, Chin KJ, Semenova E, Seregard S, Fili M, Wilson M, Haik B, Caminal JM, Català J, Gutierrez C, Pelayes DE, Folgar AM, Jager MJ, Dogrusöz M, Luyten GPM, Singh A, Schachat AP, Suzuki S, Aihara Y (2016) Local recurrence significantly increases the risk of metastatic uveal melanoma. Ophthalmology 123:86–91. https://doi.org/10.1016/j.ophtha.2015.09.014

    Article  Google Scholar 

  23. 23.

    Konstantinidis L, Groenewald C, Coupland SE, Damato B (2014) Trans-scleral local resection of toxic choroidal melanoma after proton beam radiotherapy. Br J Ophthalmol 98:775–779. https://doi.org/10.1136/bjophthalmol-2013-304501

    Article  PubMed  Google Scholar 

  24. 24.

    Daftari IK, Char DH, Verhey LJ, Castro JR, Petti PL, Meecham WJ, Kroll S, Blakely EA (1997) Anterior segment sparing to reduce charged particle radiotherapy complications in uveal melanoma. Int J Radiat Oncol Biol Phys 39:997–1010

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Alexander Böker.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee (name of institute/committee) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Human and animal rights and informed consent

For this type of study, formal consent is not required.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Böker, A., Pilger, D., Cordini, D. et al. Neoadjuvant proton beam irradiation vs. adjuvant ruthenium brachytherapy in transscleral resection of uveal melanoma. Graefes Arch Clin Exp Ophthalmol 256, 1767–1775 (2018). https://doi.org/10.1007/s00417-018-4032-7

Download citation

Keywords

  • Uveal melanoma
  • Neoadjuvant proton beam radiotherapy
  • Adjuvant ruthenium brachytherapy
  • Transscleral resection